Athenex Reports Positive Early Signals of Clinical Trial of Tirbanibulin With Psoriasis Patients | Glenrock Gazette

Athenex Reports Positive Early Signals of Clinical Trial of Tirbanibulin With Psoriasis Patients

Athenex (ATNX) and biopharmaceutical company PharmaEssentia Corp. (TWSE:6446) on Thursday outlined positive early signals in patients with psoriasis who were treated with KX2-391 (INN:tirbanibulin) 1% ointment once a day for five days in a phase 1 clinical trial.

The study involved six patients with mild to moderate psoriasis. All patients showed some improvement after the treatment, the companies said.

The World Health Organization has recommended tirbanibulin as the International Nonproprietary Name (INN) for KX2-391.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Athenex said it has licensed the rights to tirbanibulin to PharmaEssentia for psoriasis and non-malignant skin conditions, excluding actinic keratosis, in Mainland China, Taiwan, Hong Kong, Macau, Singapore and Malaysia, as well as the rights for actinic keratosis in Taiwan.

PharmaEssentia is sponsoring the phase 1 clinical trial in psoriasis. Athenex also licensed the rights to tirbanibulin for any skin disorder or skin disease in humans, including any skin cancer treated by dermatologists in the U.S. and in European countries, including Russia, to Almirall, S.A.